Company / Cash & Equivalents
KIORA PHARMACEUTICALS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.7M
FY2025
5-year range
$1.2M / $8.7M
FY2021-FY2025
Trend
+129.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $1M to $9M over the past 4 years.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +49.0%.
Improved from $1M to $9M over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +49.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +49.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 129.3% year-over-year.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -5.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.7M | +129.3% |
| FY2024 | $3.8M | +219.8% |
| FY2021 | $1.2M | +0.0% |
| FY2020 | $1.2M | -68.6% |
| FY2019 | $3.8M | -52.8% |
| FY2018 | $8.0M | +2.5% |
| FY2017 | $7.8M | -7.0% |
| FY2016 | $8.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026